Skip to main content
Log in

A phase I study of toremifene

  • Symposium lectures and reports
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

A Phase I study of the new antiestrogenic drug toremifene was carried out in 27 Japanese women, using oral doses of 10–480 mg per day for one or five days. Serum concentrations reached a dose-dependent maximum 2–6 hours after each oral administration. Side effects were generally mild.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kangas L, Nieminen A, Blanco G,et al.: A new triphenylethylene compound, FC-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17: 109–113, 1986

    Article  PubMed  Google Scholar 

  2. Robinson SP, Mauel DA, Jordan VC: Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur J Cancer Clin Oncol 24: 1817–1821, 1988

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tominaga, T., Abe, O., Izuo, M. et al. A phase I study of toremifene. Breast Cancer Res Tr 16 (Suppl 1), S (1990). https://doi.org/10.1007/BF01807141

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01807141

Key words

Navigation